Literature DB >> 2278719

Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil.

J Eskilsson1, M Albertsson.   

Abstract

The most common cardiotoxic effects of 5-fluorouracil (5-FU) are chest pain and ischemic ECG abnormalities. Coronary vasospasm may be the underlying mechanism. If so, prophylactic treatment with calcium channel blockers might have a beneficial effect. In the present study, prophylaxis with verapamil (120 mg three times daily) was given to 58 patients with esophageal or advanced head and neck carcinoma during induction chemotherapy with cisplatin and continuous infusion with 5-FU. Signs of ischemia appeared in 12% of the patients as compared to 13% in a previously studied compatible group of patients not receiving prophylaxis. The study does not support the hypothesis that prophylactic treatment with verapamil reduces the incidence of ischemia in patients undergoing 5-FU treatment. Verapamil might, however, modify the adverse cardiac effects of 5-FU by preventing supraventricular tachyarrhythmia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2278719     DOI: 10.3109/02841869009091790

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  28 in total

1.  5-Fluorouracil cardiotoxicity: reversible left ventricular systolic dysfunction with early detection.

Authors:  Muhammad Zaid Iskandar; Wahid Quasem; Magdi El-Omar
Journal:  BMJ Case Rep       Date:  2015-05-02

2.  5-Fluorouracil-induced cardiotoxicity during chemotherapy for adenocarcinoma of the small bowel.

Authors:  Mohamed H Abou El Fadl; Rajesh K Bagai; Timothy P Spiro; Hamad A Daw
Journal:  Gastrointest Cancer Res       Date:  2009-07

3.  Treatment of advanced colorectal cancer in a patient with cardiotoxic reactions to 5-fluorouracil and capecitabine using suboptimal doses.

Authors:  Joseph H Cioffi; Derek J Estes; Vaia Florou; Bach Ardalan
Journal:  BMJ Case Rep       Date:  2017-11-27

Review 4.  Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers.

Authors:  Kelly C Gast; Paul V Viscuse; Somaira Nowsheen; Tufia C Haddad; Robert W Mutter; Andrea E Wahner Hendrickson; Fergus J Couch; Kathryn J Ruddy
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-01

5.  Rapidly developing heart failure from capecitabine cardiotoxicity: a case study.

Authors:  Paurush Ambesh; Kaveh Zivari; Chukwudi Obiagwu; Vijay Shetty; Stephan Kamholz; Gerald Hollander; Jacob Shani
Journal:  Br J Clin Pharmacol       Date:  2018-02-09       Impact factor: 4.335

6.  Successful 5-fluorouracil (5-FU) infusion re-challenge in a metastatic colorectal cancer patient with coronary artery disease who experienced symptoms consistent with coronary vasospasm during first 5-FU infusion.

Authors:  Jason M Redman; Logan P Rhea; Alessandra Brofferio; Margaret Whelpley; James L Gulley; Margaret E Gatti-Mays; Sheri McMahon; Lisa M Cordes; Julius Strauss
Journal:  J Gastrointest Oncol       Date:  2019-10

Review 7.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors:  V B Pai; M C Nahata
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

Review 8.  Cardiotoxicity of cancer chemotherapy: implications for children.

Authors:  Valeriano C Simbre; Sarah A Duffy; Gul H Dadlani; Tracie L Miller; Steven E Lipshultz
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

9.  Capecitabine-induced cardiotoxicity: case report and review of the literature.

Authors:  C Ang; M Kornbluth; M P Thirlwell; R D Rajan
Journal:  Curr Oncol       Date:  2010-02       Impact factor: 3.677

10.  Acute coronary artery thrombosis and vasospasm following capecitabine in conjunction with oxaliplatin treatment for cancer.

Authors:  Omar Dzaye; Suzy Cleator; Petros Nihoyannopoulos
Journal:  BMJ Case Rep       Date:  2014-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.